Acelyrin, Inc.
-
Ticker
SLRN
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 51-200 Employees
- Based in Agoura Hills, California
ACELYRIN, INC. (Nasdaq: SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN’s lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease.
REPORT RATINGS
5.0 / 5.0 (1)
Acelyrin, Inc. reports have an aggregate usefulness score of 5.0 based on 1 reviews.
Acelyrin, Inc.
Most Recent Annual Report
MOST RECENT
2023 Annual Report and Form 10K